Metformin salts of salicylic acid and it congeners

Abstract

The present invention relates to compounds, intermediates used in the preparation of such compounds, processes for the preparation of such compounds of the formula VI and formula VII and such intermediates, pharmaceutical compositions comprising such compounds of the formula VI and such compounds of the formula VII, and the uses of such compounds of the formula VI and such compounds of the formula VII as antidiabetic, pre-antidiabetic, antiobesity and cardioprotective agents.

1 - 41 . (canceled) 
     
     
         42 . A compound having the formula: 
       
         
           
           
               
               
           
         
         and compounds of the formula 
       
       
         
           
           
               
               
           
         
         wherein X is H, and wherein Y +  is H 3 N + —C(═NH)—NH—C(═NH)—N—(CH 3 ) 2  and Y ++  is H 3 N+—C(═NH)—NH—C(═N + H)—N—(CH 3 ) 2 . 
       
     
     
         43 . A pharmaceutical composition comprising a compound according to  claim 42  and a pharmaceutically acceptable carrier. 
     
     
         44 . A kit comprising: a) a unit dosage comprising the compound of  claim 42 ; b) instructions on how to use the kit; and c) at least one container for holding the unit dosage forms. 
     
     
         45 . A method of treating diabetes in a mammal, including a human, comprising administering to a mammal, including a human, in need of said treatment an antidiabetic effective amount of a compound according to  claim 42  in a pharmaceutically acceptable carrier. 
     
     
         46 . A method of treating pre-diabetes in a mammal, including a human, comprising administering to a mammal, including a human, in need of said treatment a pre-antidiabetic effective amount of a compound according to  claim 42  in a pharmaceutically acceptable carrier. 
     
     
         47 . A method of treating obesity in a mammal, including a human, comprising administering to a mammal, including a human, in need of said treatment an anti-obesity effective amount of a compound according to  claim 42  in a pharmaceutically acceptable carrier. 
     
     
         48 . A method of treating obesity in a mammal, including a human, comprising administering to a mammal including a human, in need of said treatment an anti-obesity effective amount of a compound according to  claim 42  in a pharmaceutically acceptable carrier. 
     
     
         49 . A method of treating or preventing the development or progression of atherosclerotic cardiovascular disease in a mammal, including a human, comprising administering to said mammal, including a human, an effective amount of the compound according to  claim 42  in a pharmaceutically acceptable carrier. 
     
     
         50 . A method of treating or preventing the development or progression of atherosclerotic cardiovascular disease in a mammal, including a human, comprising administering to said mammal, including a human, an effective amount of the compound according to  claim 42  in a pharmaceutically acceptable carrier.